Review anchor
A disintegrin and metalloproteinase with thrombospondin motifs 13
SINGLE PROTEIN · Homo sapiens
As of 2026-09-12
Evidence Snapshot
A disintegrin and metalloproteinase with thrombospondin motifs 13
CHEMBL2346492
SINGLE PROTEIN
Homo sapiens
Identity Layer
Cross-source identity
Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.
This review treats A disintegrin and metalloproteinase with thrombospondin motifs 13 as ChEMBL target CHEMBL2346492, mapped to UniProt Q76LX8. Disease framing currently uses the Open Targets-ready proxy contract.
ChEMBL target ID
CHEMBL2346492
Primary anchor for compounds, assays, approvals, and exports
ChEMBL 36 via Core Engine
As of 2026-09-12
www.ebi.ac.uk
UniProt accession
Q76LX8
A disintegrin and metalloproteinase with thrombospondin motifs 13
UniProt accession via ChEMBL component mapping
As of 2026-09-12
www.uniprot.org
Disease evidence contract
Open Targets-ready proxy
ChEMBL drug mechanism + indication proxy
ChEMBL drug mechanism + indication proxy
As of 2026-09-12
www.ebi.ac.uk
Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.
Review-ready Target Rationale
Why A disintegrin and metalloproteinase with thrombospondin motifs 13 matters
A disintegrin and metalloproteinase with thrombospondin motifs 13 is reviewed as A disintegrin and metalloproteinase with thrombospondin motifs 13 (UniProt Q76LX8); A disintegrin and metalloproteinase with thrombospondin motifs 13 shows approved-linked disease relevance led by acquired thrombotic thrombocytopenic purpura. 2 more disease programs remain visible in the same review block.; 1 linked drug keep this evidence frame grounded.; the current evidence base includes 0 approved drugs, 4 compounds, and 3 assays, with lead potency reaching pChEMBL 4.9.
Protein context
A disintegrin and metalloproteinase with thrombospondin motifs 13
A disintegrin and metalloproteinase with thrombospondin motifs 13 Sequence length is 1427 aa.
Review this target as A disintegrin and metalloproteinase with thrombospondin motifs 13, mapped to UniProt Q76LX8. Sequence length is 1427 aa.
Protein source · UniProt accession via ChEMBL component mapping
UniProt Q76LX8
Protein
Disease context
acquired thrombotic thrombocytopenic purpura
A disintegrin and metalloproteinase with thrombospondin motifs 13 shows approved-linked disease relevance led by acquired thrombotic thrombocytopenic purpura. 2 more disease programs remain visible in the same review block. 1 linked drug keep the rationale reviewable. 2 additional disease programs remain visible in the same card. Linked drugs include APADAMTASE ALFA.
Start review with acquired thrombotic thrombocytopenic purpura because it currently carries approved-linked support. Linked drugs include APADAMTASE ALFA. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.
ChEMBL target record
Approved-linked
1 linked drug
Activity base
Portfolio and assay base
ChEMBL currently tracks 0 approved drugs, 4 compounds, and 3 assays for this target. The dominant activity type is IC50. CHEMBL2347847 is the current potency anchor at pChEMBL 4.9.
Use CHEMBL2347847 as the tractability anchor when discussing potency (pChEMBL 4.9).
Activity source · ChEMBL 36 via Core Engine
pChEMBL 4.9
Source Guidance
Start with the right source
Pick the first block or linked source that matches the review question in front of you.
Need the shortest review narrative first?
Review-ready Target Rationale
One-page rationale with as-of-date and attribution
Start with the review rationale when you need to explain why A disintegrin and metalloproteinase with thrombospondin motifs 13 matters before drilling into raw source blocks.
Jump to Review RationaleNeed stable protein naming or accession mapping?
UniProt Target Context
UniProt accession via ChEMBL component mapping
Go back to the target snapshot when you need the naming and mapping contract behind UniProt Q76LX8, not just the summarized rationale.
Open Protein ContextNeed disease fit or evidence level for program framing?
Disease Relevance & Evidence Level
ChEMBL drug mechanism + indication proxy
Use the target snapshot disease block when you need to see why acquired thrombotic thrombocytopenic purpura is currently treated as approved-linked support.
Open Disease ContextSnapshot State
No project snapshot selected. Export uses the live evidence card state.
4
Total Compounds
3
Total Assays
0
Approved Drugs
IC50: 4.0
Activity Types
pChEMBL Activity Distribution
Top 5 Inhibitors (by pChEMBL)
| Structure | Compound | pChEMBL | Type | Phase |
|---|---|---|---|---|
|
|
No preferred name
CHEMBL2347847
|
4.9 | IC50 | — |
|
|
No preferred name
CHEMBL2348091
|
4.7 | IC50 | — |
Source Header